HK1170675A1 - Method of treating atrial fibrillation - Google Patents

Method of treating atrial fibrillation

Info

Publication number
HK1170675A1
HK1170675A1 HK12111501.5A HK12111501A HK1170675A1 HK 1170675 A1 HK1170675 A1 HK 1170675A1 HK 12111501 A HK12111501 A HK 12111501A HK 1170675 A1 HK1170675 A1 HK 1170675A1
Authority
HK
Hong Kong
Prior art keywords
atrial fibrillation
treating atrial
treating
fibrillation
atrial
Prior art date
Application number
HK12111501.5A
Other languages
English (en)
Chinese (zh)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Alexander Burashnikov
John Shryock
Dewan Zeng
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1170675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HK1170675A1 publication Critical patent/HK1170675A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
HK12111501.5A 2009-12-21 2012-11-13 Method of treating atrial fibrillation HK1170675A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
HK1170675A1 true HK1170675A1 (en) 2013-03-08

Family

ID=43736345

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12111501.5A HK1170675A1 (en) 2009-12-21 2012-11-13 Method of treating atrial fibrillation

Country Status (37)

Country Link
US (3) US8513254B2 (xx)
EP (2) EP2515900B1 (xx)
JP (2) JP5723889B2 (xx)
KR (2) KR20120107995A (xx)
CN (3) CN104688739A (xx)
AP (1) AP3536A (xx)
AR (1) AR079552A1 (xx)
AU (1) AU2010339753B2 (xx)
BR (1) BR112012015499A2 (xx)
CA (1) CA2784028C (xx)
CL (1) CL2012001597A1 (xx)
CR (1) CR20120353A (xx)
CY (1) CY1116511T1 (xx)
DK (1) DK2515900T3 (xx)
EA (2) EA201691336A1 (xx)
EC (1) ECSP12012004A (xx)
ES (2) ES2646603T3 (xx)
HK (1) HK1170675A1 (xx)
HR (1) HRP20150644T1 (xx)
HU (1) HUE026916T2 (xx)
IL (1) IL220152A (xx)
ME (1) ME02179B (xx)
MX (2) MX344329B (xx)
NO (1) NO2749282T3 (xx)
NZ (2) NZ627181A (xx)
PE (1) PE20121520A1 (xx)
PL (2) PL2749282T3 (xx)
PT (2) PT2749282T (xx)
RS (1) RS54118B1 (xx)
SG (3) SG181541A1 (xx)
SI (2) SI2749282T1 (xx)
SM (1) SMT201500171B (xx)
TW (1) TWI508726B (xx)
UA (1) UA109887C2 (xx)
UY (1) UY33119A (xx)
WO (1) WO2011084733A1 (xx)
ZA (1) ZA201204608B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CA2768985C (en) 2009-07-29 2020-03-10 Icu Medical, Inc. Fluid transfer devices and methods of use
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
NO3175985T3 (xx) 2011-07-01 2018-04-28
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
WO2013112932A1 (en) * 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US20140364417A1 (en) * 2013-05-03 2014-12-11 Gilead Sciences, Inc. Method of treating atrial fibrillation
CA2919720A1 (en) * 2013-08-02 2015-02-05 Gilead Sciences, Inc. Pharmaceutical compositions of ranolazine and dronedarone
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
CN105829301A (zh) 2013-12-19 2016-08-03 吉利德科学公司 作为离子通道调节剂的稠合杂环化合物
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
JP2022518765A (ja) * 2019-01-24 2022-03-16 ノースウエスタン ユニバーシティ 心房細動の遺伝子療法による治療

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CA2019580C (en) 1989-06-23 2007-03-27 Robert J. Dow Novel methods of treatment using ranolazine and related piperazine derivatives
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
ATE357257T1 (de) * 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
CA2433861A1 (en) 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
IL159614A0 (en) * 2001-07-20 2004-06-01 Karobio Ab Benzofuran derivatives and pharmaceutical compositions containing the same
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GEP20094784B (en) 2005-01-06 2009-09-25 Cv Therapeutics Inc Sustained release pharmaceutical formulations
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
WO2008100992A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Intravenous solutions comprising ranolazine
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2337559A2 (en) 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation

Also Published As

Publication number Publication date
CN102665713A (zh) 2012-09-12
SG181541A1 (en) 2012-07-30
HUE026916T2 (en) 2016-08-29
US20140323493A1 (en) 2014-10-30
AU2010339753B2 (en) 2015-01-22
PL2749282T3 (pl) 2018-01-31
NZ627181A (en) 2016-02-26
EP2515900B1 (en) 2015-04-29
EA201691336A1 (ru) 2017-05-31
US9056108B2 (en) 2015-06-16
EA201290451A1 (ru) 2013-01-30
TW201136586A (en) 2011-11-01
DK2515900T3 (en) 2015-07-27
AP2012006331A0 (en) 2012-06-30
PL2515900T3 (pl) 2015-10-30
CN104688739A (zh) 2015-06-10
MX2012007052A (es) 2012-07-30
KR20160108611A (ko) 2016-09-19
PE20121520A1 (es) 2012-11-26
AU2010339753A1 (en) 2012-07-12
HRP20150644T1 (hr) 2015-07-31
AP3536A (en) 2016-01-13
TWI508726B (zh) 2015-11-21
CR20120353A (es) 2014-10-07
CA2784028C (en) 2016-08-23
ME02179B (me) 2015-10-20
ZA201204608B (en) 2013-02-27
RS54118B1 (en) 2015-12-31
KR20120107995A (ko) 2012-10-04
US8754087B2 (en) 2014-06-17
NZ600718A (en) 2014-08-29
ECSP12012004A (es) 2012-08-31
JP2013515007A (ja) 2013-05-02
BR112012015499A2 (pt) 2016-05-03
NO2749282T3 (xx) 2018-01-06
AR079552A1 (es) 2012-02-01
CA2784028A1 (en) 2011-07-14
WO2011084733A1 (en) 2011-07-14
CY1116511T1 (el) 2017-03-15
SG10201408528RA (en) 2015-04-29
US8513254B2 (en) 2013-08-20
SI2749282T1 (sl) 2017-12-29
EP2515900A1 (en) 2012-10-31
EA025445B1 (ru) 2016-12-30
EP2749282B1 (en) 2017-08-09
IL220152A (en) 2016-11-30
JP5723889B2 (ja) 2015-05-27
MX344329B (es) 2016-12-13
UY33119A (es) 2011-07-29
ES2540093T3 (es) 2015-07-08
SI2515900T1 (sl) 2015-07-31
UA109887C2 (uk) 2015-10-26
PT2749282T (pt) 2017-11-15
EP2749282A1 (en) 2014-07-02
SMT201500171B (it) 2015-09-07
US20130317038A1 (en) 2013-11-28
CN102665713B (zh) 2015-02-18
CN104147010A (zh) 2014-11-19
JP2015057449A (ja) 2015-03-26
PT2515900E (pt) 2015-07-30
IL220152A0 (en) 2012-07-31
SG10201710751TA (en) 2018-02-27
ES2646603T3 (es) 2017-12-14
US20110183990A1 (en) 2011-07-28
CL2012001597A1 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
AP3536A (en) Method of treating atrial fibrillation
EP2558014A4 (en) Methods and devices for treating atrial fibrillation
EP2421607A4 (en) DEVICE AND METHOD FOR PROOFING AND TREATING PREVIOUS LAYOUMS
IL208354A0 (en) Methods of treatment
HK1254495A1 (zh) 舒巴林用於治療心房纖顫的用途
IL214664A0 (en) Methods of treating hair related conditions
EP2350641A4 (en) Methods of Treatment
GB201018147D0 (en) Method of treatment
GB201003920D0 (en) Method of treatment
EP2473232A4 (en) METHOD AND DEVICE FOR TREATING HEART RADIATOR DISORDERS
ZA201108493B (en) Method of treating hair
ZA201005206B (en) Method of treating hair
IL216456A0 (en) Method of treating frailty
EP2585103A4 (en) METHOD OF TREATMENT
GB201018149D0 (en) Method of treatment
HK1204262A1 (en) Method of treating atrial fibrillation
GB201020015D0 (en) Method of treatment
AU2011904917A0 (en) Method for preventing and/or treating atrial fibrillation
GB0823435D0 (en) Method of treatment
GB0909807D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0900624D0 (en) Method of treating wool
GB201005071D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191225